Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb;11(2):369-372.
doi: 10.21037/jtd.2018.12.55.

The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer

Pradnya D Patil  1 , Brian Hobbs  2 , Nathan A Pennell  1
Affiliations
Editorial

The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer

Pradnya D Patil et al. J Thorac Dis. 2019 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: N Pennell has consulted with Eli Lilly, AstraZeneca, Regeneron, and Merck. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. Erratum in: N Engl J Med 2007;356:318. 10.1056/NEJMoa061884 - DOI - PubMed
    1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. 10.1200/JCO.2007.15.0375 - DOI - PubMed
    1. Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2015;26:1415-21. 10.1093/annonc/mdv208 - DOI - PubMed
    1. Schneider F, Smith MA, Lane MC, et al. Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas. Am J Clin Pathol 2015;143:193-200; quiz 306. 10.1309/AJCPMY8UI7WSFSYY - DOI - PubMed
    1. Lee B, Lee T, Lee SH, et al. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget 2016;7:23874-84. - PMC - PubMed